Shouvik Dass - Concepedia

Author

Shouvik Dass

University of Leeds ORCID

Also Known As

Dass, Shouvik, S. Thulasi Dass, Shouvik Dass

Publications

1.5K

Citations

H-Index

Concepts

All Affiliations

University of Leeds Leeds Teaching Hospitals NHS Trust NIHR Leeds Musculoskeletal Biomedical Research Unit Chapel Allerton Hospital National Institute for Health Research

About

Shouvik Dass is an author at University of Leeds specializing in immunology, rheumatology, and rheumatoid arthritis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	1	1	10
2	Immunology	1	1	10
3	Rheumatology	1	1	10
4	Autoimmune Disease	1	1	10
5	Rheumatoid Arthritis	1	1	10

Shouvik Dass

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
B cell biomarkers of rituximab responses in systemic lupus erythematosus Edward M Vital, Shouvik Dass, Maya H Buch, Arthritis & Rheumatism	2011	232
Development of psoriasis after B cell depletion with rituximab Shouvik Dass, Edward M Vital, Paul Emery Arthritis & Rheumatism	2007	231
Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis Shouvik Dass, Andy C. Rawstron, Edward M Vital, Arthritis & Rheumatism	2008	209
Effect of rituximab on the progression of rheumatoid arthritis–related interstitial lung disease: 10 years’ experience at a single centre Md Yuzaiful Md Yusof, Angela Kabia, Michael Darby, Lara D. Veeken	2017	203
Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases Md Yuzaiful Md Yusof, Edward M Vital, Damien McElvenny, Arthritis & Rheumatology	2019	112
Reduced-dose rituximab in rheumatoid arthritis: Efficacy depends on degree of B cell depletion Edward M Vital, Andy C. Rawstron, Shouvik Dass, Arthritis & Rheumatism	2010	87
An extra dose of rituximab improves clinical response in rheumatoid arthritis patients with initial incomplete B cell depletion: a randomised controlled trial Edward M Vital, Shouvik Dass, Maya H Buch, Annals of the Rheumatic Diseases	2014	55
Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study Md Yuzaiful Md Yusof, Jack Arnold, Benazir Saleem, The Lancet Rheumatology	2023	50
Efficacy and safety of obinutuzumab in systemic lupus erythematosus patients with secondary non-response to rituximab Jack Arnold, Shouvik Dass, Sarah Twigg, Lara D. Veeken	2022	49
Repeat cycles of rituximab on clinical relapse in ANCA-associated vasculitis: identifying B cell biomarkers for relapse to guide retreatment decisions Md Yuzaiful Md Yusof, Edward M Vital, Sudipto Das, Annals of the Rheumatic Diseases	2015	38

Page 1